Sanofi SA's Lyxumia (lixisenatide) showed more pronounced after-test-meal blood sugar lowering than liraglutide when both were added to insulin glargine


Sunday, 15 Jun 2014 01:02pm EDT 

Sanofi SA:Announces that Lyxumia (lixisenatide) met primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide.Showing significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus (insulin glargine).Lowering of post-prandial glucose was measured as change from baseline in incremental area under glucose curve for four hours after standardized solid breakfast, at week 8.Findings also showed that while both lixisenatide and liraglutide lowered blood glucose (HbA1c) when added to optimally titrated insulin glargine, lixisenatide treatment resulted in fewer reports of gastrointestinal adverse events.A lower mean increase in heart rate and smaller increases from baseline to week 8 in pancreatic enzyme (amylase and lipase) levels.Most commonly reported adverse events in study were symptomatic hypoglycemia and nausea.Symptomatic hypoglycemia was more frequent in the lixisenatide group compared to the liraglutide group.Lixisenatide is currently approved in Europe and an investigational drug in the United States, where it is not approved. 

Company Quote

87.7
0.16 +0.18%
27 Feb 2015